Slide 1: TCT 2024 Investor Update
TCT 2024 Investor Update October 30, 2024
Slide 2: Safe harbor for forward-looking statements
Safe harbor for forward-looking statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect,"
Slide 3: Regulatory disclaimers
Regulatory disclaimers ACURATE PRIME valve platform CE Marked. U.S.: Caution: Investigational Device. Limited by Federal (or U.S.) law to investigational use only. Not available for sale. ACURATE neo2 valve platform CE Marked. U.S.: Caution: Investigational Device. Limited by Federal (or U.S.) law t
Slide 4: Financial disclaimers
Financial disclaimers Market Estimates: Unless noted otherwise, all references to market sizes, market share positions, and market growth rates are BSX internal estimates. Unless noted otherwise, all references to market sizes represent 2024 estimates and all references to market growth rates repres
Slide 5: Joe Fitzgerald
Joe Fitzgerald Executive Vice President & Group President, Cardiology
Slide 6: The Cardiology group
The Cardiology group ~$38B served market in 2024E growing ~8% through 2027E Interventional Cardiology Electro- Cardiac Rhythm Management Therapies (ICTx) WATCHMAN physiology (EP) (CRM) Structural Heart Valves (SHV) Core Cardiac Cardiac Coronary Rhythm Diagnostics & Therapies (CT) Access Solutions Ma
Slide 7: Well-positioned for accelerated growth
Well-positioned for accelerated growth Achieved 23%* global growth in Cardiology YTD 2024 YTD 2024 Global Growth and Milestones * U.S. Growth 27% * International Growth 18% 12%* 19%* 126%* 3% * ICTx WATCHMAN EP CRM AGENT Drug-Coated Balloon WATCHMAN TruSteer FARAPULSE Pulsed Field Ablation INGEVITY
Slide 8: Significant growth drivers throughout the portfolio
Significant growth drivers throughout the portfolio Interventional Cardiology Therapies Cardiac Rhythm Management (ICTx) WATCHMAN Electro- (CRM) Coronary Structural physiology (WM) Therapies (EP) Heart Valves (CT) (SHV) Core CRM Diagnostics (Dx) FARAPULSE PFA System LUX-Dx II+ and AGENT Drug- mCRM L
Slide 9: Lance Bates
Lance Bates Global President, Interventional Cardiology Therapies
Slide 10: 2024E served markets $15B
2024E served markets $15B Growing ~8% through 2027E Drug Eluting Therapies Complex PCI PCI-Guidance TAVR $3.1B $4.2B $1.3B $6.7B HSD Growth HSD Growth LDD Growth HSD Growth SYNERGY XD Stent System ACURATE Prime ROTAPRO Rotational AVVIGO + Multi Modality Atherectomy Device Aortic Valve System AGENT D
Slide 11: AGENT DCB & AVVIGO+ Imaging
AGENT DCB & AVVIGO+ Imaging Broad portfolio to provide right tools at right time Driving broad portfolio usage through proper imaging and vessel preparation in AGENT DCB cases AVVIGO + Multi-Modality Guidance System AGENT Drug-Coated Balloon Launched in 45+ countries IVUS use occurred in Potential g
Slide 12: Dr. Janar Sathananthan
Dr. Janar Sathananthan Chief Medical Officer, Interventional Cardiology Therapies
Slide 13: ACURATE IDE Trial Design
ACURATE IDE Trial Design Largest randomized, head-to-head comparison of ACURATE & commercial TAVR platforms Trial complexity: 1,500 all-risk patients enrolled nearly four years during global COVID-19 pandemic Enrollment pace: Nearly four-year enrollment, with average of 2.9 months between each sites
Slide 14: ACURATE IDE Primary Endpoint
ACURATE IDE Primary Endpoint Primary Endpoint through 1-Year ACURATE Implant Quality Analysis Death, stroke or rehospitalization† Parallel Commissure Posts → Non-Parallel Commissure Posts → Expanded Valve Under-Expanded Valve Posterior Median & 95% BCI Non-Inferiority Test Posterior Non- Median ACUR
Slide 15: ACURATE IDE Post-Hoc Analysis
ACURATE IDE Post-Hoc Analysis Analyzed outcomes for expanded & under-expanded valve frame Time-to-Event Analysis through 1 Year Death, stroke, or rehospitalization† Post-Hoc Clinical Analysis: Valve Frame Expansion (N=1433 Subjects) The rate of the composite endpoint of death, stroke, or rehospitali
Slide 16: ACURATE IDE Post-Hoc Analysis
ACURATE IDE Post-Hoc Analysis Analyzed outcomes for expanded & under-expanded valve frame Time-to-Event Analysis through 1 Year Time-to-Event Analysis through 1 Year Death Stroke Post-Hoc Clinical Analysis: Valve Frame Expansion Post-Hoc Clinical Analysis: Valve Frame Expansion (N=1433 Subjects) (N=
Slide 17: ACURATE neo2 Outcomes Analysis
ACURATE neo2 Outcomes Analysis ACURATE valve under-expansion a potential contributing factor to clinical events Expanded ACURATE neo2 valve • Laminar flow • Adequate washout Under-expanded ACURATE neo2 valve • Turbulent flow • Reduced washout
Slide 18: ACURATE Prime Aortic Valve System
ACURATE Prime Aortic Valve System Differentiated features to drive platform adoption globally Launched in Europe October 17, 2024 EXPANDED TREATMENT RANGE Limited Market Release 20.5mm – 29mm progressing well VALVE FRAME ENHANCEMENT Equalized distribution of radial force QUICK RELEASE 90 degree quic
Slide 19: Other Relevant TCT Data
Other Relevant TCT Data PROTECTED TAVR Post-Hoc Analysis AGENT DCB Subgroup Analyses HEAL-LAA Primary Endpoint • 1,833 patients enrolled in U.S. • Three subgroup analyses from 600- • First 500 patients enrolled • TAVR with SENTINEL Cerebral patient AGENT IDE trial - first RCT of Protection System as
Slide 20: APPENDIX
Boston, Scientific Advancing science for life APPENDIX
Slide 21: Supplemental non-GAAP disclosures
Supplemental non-GAAP disclosures Nine Months Ended September 30, 2024 Impact of Foreign Reported Currency Operational Cardiology Net Sales Growth by Business Unit Basis Fluctuations Basis Interventional Cardiology Therapies 10 % 2.1 % 12 % Watchman 19 % 0.3 % 19 % Cardiac Rhythm Management 3% 0.4 %